PPLPHARMA.NS
Cash Flow
Piramal Pharma Ltd. · Healthcare
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-09-23 02:33
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹483.89 Cr. | ₹1,004.54 Cr. | ₹892.30 Cr. | ₹1,652.59 Cr. | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-1,338.78 Cr. | ₹-434.01 Cr. | ₹-477.46 Cr. | ₹-826.03 Cr. | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹817.79 Cr. | ₹-422.36 Cr. | ₹-440.83 Cr. | ₹-38.97 Cr. | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹5.15 Cr. | ₹17.79 Cr. | ₹-10.88 Cr. | ₹6.35 Cr. | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹-31.95 Cr. | ₹165.96 Cr. | ₹-36.87 Cr. | ₹793.94 Cr. | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹85.18 Cr. | ₹53.23 Cr. | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
| Dividends Paid | ₹67.00 Cr. | ₹0.00 Cr. | ₹14.47 Cr. | ₹18.55 Cr. | DividendsPaidClassifiedAsFinancingActivities |
Every figure above is the exact value of the named XBRL element from PPLPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).